Theravance Biopharma Inc (NASDAQ:TBPH) has received an average rating of “Hold” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $41.33.

TBPH has been the subject of a number of recent research reports. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a report on Tuesday, December 5th. Robert W. Baird reissued a “sell” rating and issued a $22.00 price objective on shares of Theravance Biopharma in a report on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating and set a $37.00 price objective for the company in a report on Tuesday, October 10th.

Shares of Theravance Biopharma (TBPH) opened at $26.98 on Monday. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21. The stock has a market cap of $1,460.00, a PE ratio of -5.23 and a beta of 2.35. Theravance Biopharma has a twelve month low of $23.15 and a twelve month high of $43.44.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.05). Theravance Biopharma had a negative net margin of 1,604.87% and a negative return on equity of 99.43%. equities research analysts expect that Theravance Biopharma will post -4.84 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Moneta Group Investment Advisors LLC acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at approximately $299,000. Schwab Charles Investment Management Inc. raised its position in shares of Theravance Biopharma by 8.0% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 191,558 shares of the biopharmaceutical company’s stock valued at $6,559,000 after buying an additional 14,241 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Theravance Biopharma by 32.0% in the 3rd quarter. Wells Fargo & Company MN now owns 117,079 shares of the biopharmaceutical company’s stock valued at $4,009,000 after buying an additional 28,391 shares in the last quarter. Legal & General Group Plc raised its position in shares of Theravance Biopharma by 15.7% in the 3rd quarter. Legal & General Group Plc now owns 18,840 shares of the biopharmaceutical company’s stock valued at $646,000 after buying an additional 2,551 shares in the last quarter. Finally, American International Group Inc. raised its position in shares of Theravance Biopharma by 8.1% in the 3rd quarter. American International Group Inc. now owns 28,000 shares of the biopharmaceutical company’s stock valued at $959,000 after buying an additional 2,094 shares in the last quarter. Institutional investors own 86.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Theravance Biopharma Inc (TBPH) Receives Average Rating of “Hold” from Analysts” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2018/01/14/theravance-biopharma-inc-tbph-receives-average-rating-of-hold-from-analysts.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.